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Abstract: <jats:sec>Background: In patients with acute myocardial infarction, the presence of a left
bundle branch block or right bundle branch block may be associated with worse prognosis compared
to isolated ST segment elevation. However, specificities in clinical presentation and outcomes of acute
myocardial infarction patients with left bundle branch block or right bundle branch block are poorly
characterized. </jats:sec><jats:sec>Methods: We analysed acute myocardial infarction patients with
left bundle branch block ( n=880), right bundle branch block ( n=732) or ST segment elevation with-
out bundle branch block ( n=15,852) included in the Acute Myocardial Infarction in Switzerland-Plus
registry between 2008–2019. </jats:sec><jats:sec>Results: Acute myocardial infarction patients with
bundle branch block were older and had more pre-existing cardiovascular conditions compared to ST
segment elevation. Pulmonary oedema and cardiogenic shock were most frequent in patients with left
bundle branch block (18.8% vs 12.0% for right bundle branch block and 7.9% for ST segment eleva-
tion, plt;0.001). Acute myocardial infarction patients with bundle branch block had more three-vessel
(40.6% vs 25.3%, plt;0.001 vs ST segment elevation) and left main disease (5.6% vs 2.0%, plt;0.001 vs
ST segment elevation). Major adverse cardiac and cerebrovascular events, a composite of reinfarction,
stroke/transient ischaemic attack, and death during hospitalization, were highest in acute myocardial in-
farction patients with left bundle branch block (13.9% vs 9.9% for right bundle branch block and 6.7% for
ST segment elevation, plt;0.05), which was driven by hospital mortality. After multivariate adjustment,
however, mortality was similar in patients with left bundle branch block and lower in patients with right
bundle branch block, respectively, when compared to ST segment elevation. Mortality was only increased
when a right bundle branch block with concomitant STE was present (odds ratio 1.77, 95% confidence
interval 1.19–2.64, plt;0.01 vs ST segment elevation). </jats:sec><jats:sec>Conclusions: Compared to
ST segment elevation, an isolated bundle branch block reflects high-risk clinical characteristics but does
not independently determine increased hospital mortality in acute myocardial infarction. </jats:sec>
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Background: In patients with acute myocardial infarction (AMI), the presence of a 
left bundle branch block (LBBB) or right bundle branch block (RBBB) may be 
associated with worse prognosis compared to isolated ST segment elevation (STE). 
However, specificities in clinical presentation and outcomes of AMI patients with 
LBBB or RBBB are poorly characterized. 
 
Methods: We analyzed AMI patients with LBBB (n=880), RBBB (n=732) or STE 
without bundle branch block (BBB, n=15’852) included in the Acute Myocardial 
Infarction in Switzerland (AMIS)-Plus registry between 2008 and 2019. 
 
Results: AMI patients with BBB were older and had more preexisting cardiovascular 
conditions compared to STE. Pulmonary edema and cardiogenic shock were most 
frequent in patients with LBBB (18.8% vs. 12.0% for RBBB and 7.9% for STE, 
p<0.001). AMI patients with BBB had more three-vessel (40.6% vs. 25.3%, p<0.001 
vs. STE) and left main disease (5.6% vs. 2.0%, p<0.001 vs. STE). Major adverse 
cardiac and cerebrovascular events, a composite of reinfarction, stroke/transient 
ischemic attack, and death during hospitalization, were highest in AMI patients with 
LBBB (13.9% vs. 9.9% for RBBB and 6.7% for STE, p<0.05), which was driven by 
hospital mortality. After multivariate adjustment, however, mortality was similar in 
patients with LBBB and reduced in patients with RBBB, respectively, when compared 
to STE. Mortality was only increased when an RBBB with concomitant STE was 
present (OR 1.77, 95% CI 1.19-2.64, p<0.01 vs. STE). 
 
Conclusions: Compared to STE, an isolated BBB reflects high-risk clinical 
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In patients with suspected acute myocardial infarction (AMI), a 12-lead 
electrocardiogram (ECG) must be acquired and interpreted within 10 minutes of first 
medical contact.1, 2 In the context of a suggestive clinical presentation, ST segment 
elevation (STE) frequently indicates an acute occlusion of a coronary artery.1, 2 In this 
setting, a new or presumably new left bundle branch block (LBBB) or right bundle 
branch block (RBBB) may reflect a large territory of acute ischemia involving the 
proximal conducting system or diffusely damaging the ventricular myocardium 
leading to delayed conduction, while at the same time due to the bundle branch block 
(BBB) the STE may be concealed.3 Therefore, European Society of Cardiology 
(ESC) guidelines not only recommend urgent coronary angiography in AMI patients 
with STE, but likewise also with a (presumably) new LBBB or RBBB and signs or 
symptoms of ongoing myocardial ischemia.2 This treatment recommendation is 
based on retrospective analyses and on the fact that the ECG, the cornerstone of 
diagnosis, is frequently not interpretable. However, patients with suspected AMI and 
LBBB or RBBB represent a much more heterogeneous population with a lower 
probability of an occluded culprit artery compared to patients with isolated STE.3 
 
Specificities in clinical presentation and outcomes of AMI patients with LBBB or 
RBBB have been poorly characterized, and previous studies have yielded conflicting 
results regarding the prognostic significance of an LBBB or RBBB in this setting. In 
contrast to a preexisting BBB, a new or presumably new, persistent LBBB or RBBB 
in patients with AMI was found to be an independent predictor of short- or long-term 
mortality in most,4-15 but not in all studies.16, 17 In addition, while some authors 
reported increased mortality in AMI patients presenting with an LBBB compared with 
an RBBB,5, 13 others found the opposite4, 8, 14, 15 or no difference.7, 9, 10, 16 However, 




to the fibrinolytic era when coronary angiography and coronary revascularization 
were not routinely performed, or represented post hoc analyses of randomized trials. 
We therefore addressed specificities of clinical presentation and outcomes in AMI 
patients with LBBB or RBBB and compared them with the isolated STE population in 






Acute Myocardial Infarction in Switzerland (AMIS)-Plus registry 
The AMIS-Plus registry was initiated in 1997 and collects data from patients admitted 
with an acute coronary syndrome to one of 84 contributing Swiss hospitals, ranging 
from community hospitals to large tertiary care facilities, as described previously.18 
Anonymized data are provided by the treating physician or a trained study nurse via 
electronic or paper-based forms, and checked for completeness, plausibility and 
consistency by the AMIS-Plus data center (Epidemiology, Biostatistics and 
Prevention Institute, University of Zurich, Switzerland). Data acquisition and analysis 
are performed in accordance with good clinical practice guidelines, undergo regular 
external auditing, and have been approved by the supra-regional and cantonal ethics 
committees of all participating hospitals. The ethics committees waived the 
requirement to obtain patients’ informed consent. 
 
Study population and outcomes 
This investigation analyzed data from AMI patients enrolled in the AMIS-Plus registry 
between January 2008 and June 2019 with either an LBBB, RBBB, or STE in the 
ECG on admission. A final diagnosis of AMI required the detection of a rise and/or 
fall in cardiac troponin I or T values, with at least one value above the 99th percentile 
upper reference limit.19-21 If troponin assays were unavailable, an increase in creatine 
kinase myocardial band (CK-MB) level ≥2-fold above the upper reference limit was 
accepted. The choice of the cardiac biomarker assay used was at the discretion of 
the contributing hospital. In addition, clinical evidence of acute myocardial ischemia 
including typical symptoms or new ischemic ECG changes were required.19-21 LBBB 
and RBBB were considered new or presumably new by the treating physician, and 




the Charlson index.22 A >50% stenosis in the coronary angiogram was considered 
significant as diagnosed by the treating interventional cardiologist. 
As primary outcome, we analyzed major adverse cardiac and cerebrovascular events 
(MACCE), representing a composite of reinfarction, stroke/transient ischemic attack 
(TIA), and/or death during hospitalization. Secondary outcomes included the 
individual components of the primary outcome, as well as cardiogenic shock and 
acute renal failure during hospitalization. Reinfarction was defined as the presence of 
recurrent ischemic symptoms or clinical signs following the initial MI, with at least a 
20% increase in cardiac biomarkers during repeated sampling. Stroke and TIA were 
defined as the presence of a new focal neurologic deficit thought to be of vascular 
origin, with signs or symptoms lasting more or less than 24 h, respectively. 
Cardiogenic shock was diagnosed when hypotension (systolic blood pressure 
<90mmHg) despite adequate filling status was associated with evidence of 
hypoperfusion, and acute renal failure was defined as described.23 
 
Statistical analyses 
Demographic and clinical characteristics, therapeutic strategies and hospital 
outcomes were analyzed stratified according to the findings in the initial ECG. 
Normally distributed data were analyzed using the unpaired Student’s t test and 
given as mean ± standard deviation (SD). Non-normally distributed data were 
analyzed using the nonparametric Mann-Whitney U test and given as median and 
interquartile range (IQR). Categorical data were analyzed by the Fisher’s exact or the 
Pearson χ2 test, as appropriate. To study the association of BBBs with hospital 
mortality, multivariate logistic regression modeling using the following covariates was 
performed: isolated LBBB, isolated RBBB, isolated STE, combined LBBB and STE, 
combined RBBB and STE, age, female sex, resuscitation prior to admission, Killip 
class ≥3, Charlson comorbidity index, performance of PCI, as well as heart rate, 




with 95% confidence intervals (CI). All analyses were performed using IBM SPSS 
Statistics software (version 24, IBM Corp., Armonk, NY). Two-sided P values <0.05 







Between January 1st 2008 and June 30th 2019, 33’157 AMI patients were included in 
the AMIS-Plus registry. Of these, 15’291 patients (46%) without STE or a BBB and 
402 patients (1.2%) with missing ECG data were excluded from the analysis. Among 
the remaining cohort of patients (n=17’464), 880 (5.0%) had an LBBB, 732 (4.2%) 
had an RBBB, and 15’852 (90.8%) had isolated STE in the initial ECG, and these 
three groups were compared in the current investigation. Baseline characteristics are 
shown in Table 1. Compared to the group with RBBB, AMI patients with an LBBB 
were older and had a higher percentage of women. Patients with LBBB also more 
frequently had hypertension, coronary artery disease, heart failure, and kidney 
disease (all p<0.05 vs. RBBB). Compared to isolated STE, AMI patients with LBBB 
or RBBB were ~10 years older and had more comorbidities, including a higher 




 LBBB (n=880) RBBB (n=732) STE (n=15’852) P value  
(LBBB vs. RBBB) 
P value  
(BBB vs. STE) 
Demographic characteristics 
Age (years), mean±SD 75.6±10.3 73.1±11.4 64.2±13.0 <0.001 <0.001 
Sex (female), % (n/N) 32.7 (288/880) 16.8 (123/732) 25.9 (3’961/15’852) <0.001 <0.001 
Medical history, % (n/N) 
Hypertension 83.6 (694/830) 76.3 (530/695) 56.8 (8’428/14’828) <0.001 <0.001 
Diabetes 31.6 (265/838) 29.0 (203/700) 17.2 (2’578/14’957) 0.29 <0.001 
Dyslipidemia 67.5 (512/758) 66.9 (429/641) 57.7 (8’046/13’949) 0.82 <0.001 
Smoking 20.3 (142/699) 28.2 (168/595) 45.4 (6’200/13’658) 0.001 <0.001 
Obesity (BMI >30 kg/m2) 22.9 (169/738) 23.1 (149/645) 20.5 (2’910/14’221) 0.95 0.03 
Coronary artery disease 52.6 (439/834) 46.3 (321/693) 22.2 (3’370/15’174) 0.02 <0.001 
Heart failure 11.0 (94/851) 4.4 (31/712) 1.8 (281/15’309) <0.001 <0.001 
Cerebrovascular disease 10.1 (86/851) 8.8 (63/712) 4.0 (608/15’359) 0.44 <0.001 
Peripheral artery disease 9.5 (81/851) 7.4 (53/712) 3.6 (556/15’359) 0.15 <0.001 
Kidney disease 21.0 (177/842) 15.0 (105/700) 4.9 (744/15’227) <0.01 <0.001 
Charlson comorbidity index >1 46.7 (393/842) 38.9 (272/700) 16.7 (2’531/15’176) <0.01 <0.001 
 
Table 1. Baseline characteristics of AMI patients according to initial ECG. BBB, bundle branch block; BMI, body mass index; LBBB, left 




Most patients presented with chest pain, particularly in the presence of AMI with STE 
(95% vs. 81% of the patients with LBBB or RBBB, p<0.001, Table 2). Half of the 
patients with LBBB had dyspnea, which was 22% and 46% less common in the 
presence of an RBBB or STE, respectively. Approximately 19% of patients with 
LBBB presented with pulmonary edema or cardiogenic shock, conditions that were 
1.5- and 2.4-fold more frequent than in patients with RBBB and STE, respectively. Of 
the three groups of patients, individuals with LBBB also had the highest creatinine 
levels, and the longest hospital stays. In contrast, based on peak creatine kinase 
levels, infarct size was about 4-times larger if the initial ECG showed STE as 
compared with LBBB or RBBB. Of those patients who underwent coronary 
angiography (n=16’344, 94% of the patient cohort), about 40% with BBB had three-
vessel coronary artery disease (vs. 25.3% of patients with STE, p<0.001, Figure 1), 
whereas patients with STE more frequently had single vessel coronary artery 





 LBBB (n=880) RBBB (n=732) STE (n=15’852) P value  
(LBBB vs. RBBB) 
P value  
(BBB vs. STE) 
Chest pain, % (n/N) 81.3 (659/811) 81.5 (552/677) 95.4 (14’548/15’252) 0.95 <0.001 
Dyspnea, % (n/N) 53.9 (416/772) 42.3 (265/627) 29.0 (3’914/13’502) <0.001 <0.001 
Systolic BP (mmHg), mean±SD 137±30 139±28 132±28 0.26 <0.001 
Heart rate (bpm), mean±SD 86±24 82±22 79±19 <0.001 <0.001 
Atrial fibrillation, % (n/N) 11.4 (100/880) 9.3 (68/732) 3.8 (598/15’839) 0.19 <0.001 
Killip class ≥3, % (n/N) 18.8 (164/874) 12.0 (87/728) 7.9 (1’244/15’733) <0.001 <0.001 
Resuscitation prior to admission, 
% (n/N) 
7.5 (66/880) 9.0 (66/732) 7.9 (1’257/15’842) 0.28 0.47 
Patient delay (min), median (IQR) 230 (104, 719) 301 (116, 943) 165 (91, 370) 0.07 <0.001 
Creatinine (mol/L), median 
(IQR) 
96 (78, 128) 93 (70, 116) 83 (70, 98) <0.001 <0.001 
Peak CK (IU/L), median (IQR) 346 (159, 816) 354 (171, 889) 1288 (497, 2’664) 0.06 <0.001 
Hospital stay (days), median 
(IQR) 
5 (2, 10) 5 (2, 9) 4 (2, 7) 0.02 <0.001 
 
Table 2. Clinical presentation of AMI patients according to initial ECG. BBB, bundle branch block; BP, blood pressure; bpm, beats per 




The incidence of MACCE was highest in AMI patients with LBBB (13.9% vs. 9.9% 
and 6.7% in patients with RBBB and STE, respectively, p<0.05, Table 3), which was 
largely driven by the crude hospital mortality (12.8% vs. 8.9% and 5.6% in patients 
with RBBB and STE, respectively, p<0.05). Notable was also a ~2-fold higher 
incidence of cardiogenic shock developing during hospitalization in this patient 
population (7.6% vs. 3.9% and 3.8% in patients with RBBB and STE, respectively, 
p<0.05), whereas the incidence of reinfarction and stroke did not differ between 
groups. Acute renal failure was 2.4-times more common in patients with BBB (5.1% 
vs. 2.1% in patients with STE, p<0.001). After multivariate adjustment, hospital 
mortality was similar in the presence of an isolated LBBB compared to STE, while 
the presence of an isolated RBBB was associated with reduced mortality. In contrast, 
increased mortality was observed when an RBBB (but not LBBB) with concomitant 
STE was present in the initial ECG of AMI patients (OR 1.77, 95% CI 1.19-2.64, 
p=0.005 vs. STE, Figure 2). In the overall patient population, resuscitation prior to 
admission as well as presentation in Killip class ≥3 were most closely associated with 
hospital mortality. Increased mortality was also independently associated with a 
Charlson comorbidity index >1, increased age, heart rate and creatinine values, while 




 LBBB (n=880) RBBB (n=732) STE (n=15’852) P value  
(LBBB vs. RBBB) 
P value  
(BBB vs. STE) 
Primary outcome, % (n/N)      
MACCE 13.9 (121/871) 9.9 (71/720) 6.7 (1045/15’675) 0.02 <0.001 
Secondary outcomes, % (n/N)      
Reinfarction 0.7 (6/871) 1.1 (8/720) 0.8 (127/15’675) 0.43 0.55 
Stroke/TIA 0.9 (8/871) 1.3 (9/720) 0.7 (113/15’675) 0.63 0.09 
Mortality 12.8 (113/880) 8.9 (65/732) 5.6 (885/15’852) 0.01 <0.001 
Cardiogenic shock 7.6 (66/870) 3.9 (28/720) 3.8 (596/15’663) <0.01 0.01 
Acute renal failure 5.7 (50/871) 4.3 (31/720) 2.1 (328/15’666) 0.21 <0.001 
 
Table 3. Primary and secondary hospital outcomes of AMI patients according to initial ECG. BBB, bundle branch block; LBBB, left 
bundle branch block; MACCE, major adverse cardiac and cerebrovascular events (a composite of reinfarction, stroke/TIA, and/or death); 
RBBB, right bundle branch block; STE, ST segment elevation; TIA, transient ischemic attack. 
15 
 
Therapy and outcomes in AMI patients undergoing primary PCI 
The use of percutaneous coronary intervention (PCI) as the selected treatment 
strategy over the study period is shown in Figure 3. In all groups, the left anterior 
descending coronary artery was most frequently treated (~47% of patients, p=n.s. 
between groups). When compared to AMI patients with STE, more interventions to 
the left main (7.2% vs. 2.7%, p<0.001) and circumflex artery (31.4% vs. 18.2%, 
p<0.001) were performed in AMI patients with LBBB or RBBB, whereas the right 
coronary artery was less frequently treated (31.1% vs. 42.5%, p<0.001). Regarding 
the concomitant pharmacological therapy, antithrombotic medications were more 
likely to be administered to patients with STE, whereas diuretics and vasopressors 
were more frequently used in patients with LBBB (Table 4). 
 
Crude hospital mortality was lower in patients subjected to a primary PCI strategy 
when compared to the overall cohort (Tables 3 and 4). However, MACCE and 
hospital mortality of AMI patients with BBB remained 1.9-fold (LBBB) and 1.8-fold 
(RBBB) higher compared to STE (MACCE: 9.5% vs. 9.1% vs. 5.5%, p<0.001 vs. 
STE; mortality: 8.6% vs. 8.1% vs. 4.5%, p<0.001 vs. STE, Table 4). Patients with 
LBBB had the highest incidence of cardiogenic shock (6.8% vs. 3.8% and 3.5% in 




 LBBB (n=524) RBBB (n=484) STE (n=14’401) P value  
(LBBB vs. RBBB) 
P value  
(BBB vs. STE) 
Medical therapy, % (n/N) 
Aspirin 94.9 (488/514) 96.0 (455/474) 98.0 (13’927/14’204) 0.45 <0.001 
P2Y12 inhibitor 89.7 (462/515) 90.3 (427/473) 96.2 (13’657/14’203) 0.83 <0.001 
Heparin 84.2 (433/514) 82.8 (391/472) 92.3 (13’079/14’173) 0.61 <0.001 
GPIIb/IIIa inhibitor 7.9 (40/506) 9.5 (44/463) 24.3 (3’402/14’015) 0.42 <0.001 
Nitrate 41.4 (210/507) 45.9 (214/466) 46.8 (6’564/14’026) 0.17 0.17 
Statin 69.5 (356/512) 75.5 (357/473) 79.0 (11’163/14’129) 0.04 <0.001 
Diuretic 39.7(202/509) 28.5 (133/467) 14.3 (2’001/14’022) <0.001 <0.001 
Betablocker 51.6 (264/512) 53.1 (250/471) 53.8 (7’587/14’092) 0.66 0.46 
ACE-I/ARB 55.6 (285/513) 55.5 (261/470) 60.1 (8’499/14’131) 1.00 <0.01 
Calcium channel blocker 16.2 (82/505) 17.5 (82/468) 10.7  (1’494/13’982) 0.61 <0.001 
Vasopressor 15.0 (76/507) 10.5 (49/466) 11.1 (1’557/14’004) 0.04 0.41 
Primary outcome, % (n/N)      
MACCE 9.5 (49/517) 9.1 (43/475) 5.5 (789/14’249) 0.83 <0.001 
Secondary outcomes, % (n/N)      
Reinfarction 0.6 (3/517) 0.8 (4/475) 0.8 (114/14’249) 0.72 0.88 
Stroke/TIA 1.2 (6/517) 0.8 (4/475) 0.7 (99/14’249) 0.76 0.38 
Mortality 8.6 (45/524) 8.1 (39/484) 4.5 (643/14’401) 0.82 <0.001 
Cardiogenic shock 6.8 (35/516) 3.8 (18/475) 3.5 (495/14’239) 0.04 0.04 
Acute renal failure 5.2 (27/517) 4.2 (20/475) 2.0 (286/14’242) 0.55 <0.001 
 
Table 4. Hospital therapy and outcomes of AMI patients subjected to primary PCI according to initial ECG. ACE-I, angiotensin 
converting enzyme inhibitor; ARB, angiotensin AT1 receptor blocker; BBB, bundle branch block; LBBB, left bundle branch block; MACCE, major 
adverse cardiac and cerebrovascular events (a composite of reinfarction, stroke/TIA, and/or death); RBBB, right bundle branch block; STE, ST 






In this large prospective cohort of unselected patients admitted with AMI, we found 
that the presence of a new or presumably new BBB in the ECG at presentation was 
associated with a higher prevalence of preexisting cardiovascular disease, high-risk 
clinical features, multivessel disease, and with worse unadjusted outcomes when 
compared to isolated STE. This finding was more pronounced in the presence of an 
LBBB than an RBBB. After multivariate adjustment, mortality in the presence of an 
isolated LBBB was similar compared to STE, while an isolated RBBB was associated 
with reduced mortality. Increased hospital mortality was only observed when an 
RBBB with concomitant STE was present. This suggests that the presence of an 
isolated LBBB or RBBB reflects the patient’s higher baseline cardiovascular risk 
rather than independently contributing to adverse clinical outcomes in AMI. 
 
The presence of a BBB in AMI patients has previously been associated with 
abundant comorbidities and a high incidence of cardiogenic shock.4-13, 15-17, 24 We 
extend these findings demonstrating substantial, clinically relevant differences 
between the BBB types. Indeed, individuals with an LBBB were older, more likely to 
be female, and more frequently had a history of preexisting cardiovascular disease 
and acute heart failure on admission compared to patients with an RBBB. Given that 
more high-risk characteristics are present in AMI patients with an LBBB compared 
with an RBBB (and even more compared with isolated STE), the worse unadjusted 
outcomes may not be surprising. Indeed, older age as observed in patients with 
LBBB is strongly related not only to fibrotic changes in the conduction system leading 
to BBBs, but also potentially underlying chronic ischemic and non-ischemic 
conditions, including left ventricular hypertrophy and remodeling (most commonly 




Moreover, because it is often not possible to determine the chronicity of BBBs due to 
lack of a recent ECG before the development of an AMI, many BBBs considered 
presumably new may not result from acute myocardial ischemia, but rather reflect 
underlying structural heart disease that, in turn, increases the risk for adverse 
outcomes in AMI. Thus, the higher unadjusted mortality in AMI patients with an LBBB 
compared to patients with an RBBB (and even more compared with isolated STE) 
may be largely explained by preexisting cardiac pathologies serving as a substrate 
for conduction abnormalities.3 In line with this notion, we have previously shown that 
only clinical factors such as the Killip class and a history of heart failure, but no 
specific ECG changes, have critical discriminative performance in predicting hospital 
mortality among the AMIS-Plus cohort.25 
 
The current evidence has been conflicting regarding the independent prognostic 
value of an LBBB or RBBB in AMI patients.4, 6, 8-17, 24 However, this may be due to the 
small sample size in some registries,5, 13-16 while others date back to the fibrinolytic 
era not considering current treatment strategies, PCI in particular.4, 6, 8, 10, 16, 24 We 
report on the clinical significance of BBBs in a large contemporary prospective cohort 
of unselected AMI patients, with a high proportion treated with primary PCI reflecting 
the recommended strategy in current guidelines.1, 2 However, as with previous 
studies on patients undergoing an invasive therapeutic strategy,9, 14 the decision to 
intervene was left at the discretion of the treating physicians. The lower unadjusted 
mortality in the subset of AMI patients with LBBB or RBBB undergoing primary PCI 
may thus be confounded by a selection bias. Nevertheless, patients with BBBs still 
had worse outcomes compared to STE despite invasive therapy, supporting the 
concept of this being a risk marker reflecting preexisting heart disease. In addition, 
although the degree of myocardial damage may be related to the development of 
BBBs, they were associated with a 4-fold smaller infarct size compared to isolated 




not explain the worse clinical outcomes and (ii) that an occluded culprit artery was 
likely often not found when STE was absent. 
 
We would like to highlight that true AMI-related new BBBs carry a very high mortality 
risk, but may be challenging to recognize.1-3, 9 Our finding that an RBBB with 
concomitant STE was independently associated with increased hospital mortality 
compared to isolated STE is in line with previous observations9, 14 that such patients 
have a very high likelihood of an occluded culprit artery warranting urgent 
revascularization. Likewise, an RBBB was shown to predict mortality in STEMI, but 
not in NSTEMI patients,24 because it usually reflects a large anterior AMI involving 
the right bundle transversing the intraventricular septum typically due to occlusion of 
the proximal left anterior descending artery.3, 6 The presence of STE may be more 
difficult to recognize in the presence of an LBBB compared with an RBBB because of 
more pronounced ST-segment abnormalities.1, 2 With the exception of STE 
concordance, current ECG algorithms are complex and have limited specificity, 
which may partly explain why an LBBB with concomitant STE had similar hospital 
mortality compared with isolated STE in our study.1-3, 26 
 
The present study has certain limitations. As with all registries, even when data were 
collected prospectively, drawing conclusions on clinical outcomes needs to be done 
cautiously, because the revealed associations may not reflect actual causal links. We 
thus cannot comment on current recommendations to treat an AMI with (presumably) 
new isolated LBBB1, 2 or RBBB2 as a STEMI equivalent and, hence, it remains to be 
determined in future studies which of these very high risk patients benefit most from 
an early invasive strategy. On the other hand, randomized clinical trials often do not 
adequately represent patients with extensive comorbidities or at high age,27 which 
represents the typical population when studying AMI with BBBs. Furthermore, our 




many patients presenting with AMI do not have a previous ECG for comparison. Of 
note, ECG verification by a core laboratory is not performed in the AMIS-Plus 
registry, and we did not discriminate whether a new LBBB or RBBB was transient or 
permanent, with only the latter being an independent predictor of mortality.7, 10 
Furthermore, we report on implications that the presence of BBBs in AMI patients 
has on hospital outcomes but not on intermediate or long-term follow-up. 
 
In conclusion, an isolated BBB in patients with AMI is associated with extensive 
comorbidities, high-risk clinical features and worse unadjusted outcomes compared 
to isolated STE. However, this appears to be largely explained by underlying heart 
disease as a substrate for conduction abnormalities,3 rather than the BBB itself. 
Independently increased mortality was only observed with true AMI-related RBBB 
characterized by concomitant STE, which likely represent the patients who benefit 
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Figure 1. Severity of coronary artery disease according to initial ECG. AMI, 
acute myocardial infarction; LBBB, left bundle branch block (n=673); RBBB, right 
bundle branch block (n=597); STE, ST segment elevation (n=15’074). 
 
Figure 2. Clinical variables independently associated with hospital mortality. 
Odds ratios have been calculated using AMI patients with isolated STE as reference. 
bpm, beats per minute; CI, confidence interval; LBBB, left bundle branch block; 
RBBB, right bundle branch block; STE, ST segment elevation. 
 
Figure 3. Temporal trends in PCI performed in patients with AMI and isolated 
LBBB, RBBB or STE. AMI, acute myocardial infarction; LBBB, left bundle branch 
block; RBBB, right bundle branch block; STE, ST segment elevation. 
